ABSTRACT
BACKGROUND: Gynoid lipodystrophy is one of the most common cosmetical problems in women. AIMS: The study aims to examine the pathomorphology and histology of subcutaneous tissue in women with gynoid lipodystrophy exposed to local compression/vibration therapy using a non-invasive Beautylizer Therapy Cosmospheres V medical device. METHODS: The study enrolled 25 virtually healthy women aged 25-45 years with gynoid lipodystrophy grades I and II. The women included in the study completed a 10-session month-long therapeutic course with a non-invasive Beautylizer Therapy Cosmospheres V medical device. Bioptic punch-size samples were taken from the gluteal region prior to and following the 10-session therapy course with the device. RESULTS: After completing a 10-session treatment course, a decrease in the mean adipocyte area from 123.08 ± 13.60 µm to 67.14 ± 4.20 µm was observed in punch bioptic samples of subcutaneous fat tissues of women with gynoid lipodystrophy as compared with the pre-treatment indices. CONCLUSION: Thus, local application of 10-session therapy with a non-invasive Beautylizer Therapy Cosmospheres V medical device in women with gynoid lipodystrophy demonstrated a positive effect on the histological structure of the hypodermis.
Subject(s)
Lipodystrophy , Subcutaneous Tissue , Humans , Female , Pilot Projects , Vibration , Lipodystrophy/therapy , Lipodystrophy/pathology , Subcutaneous FatABSTRACT
Undifferentiated connective tissue dysplasia is one of the most common diseases of nowadays, which does not fit into the group of hereditary syndromes. This condition is diagnosed in 20-50% of the population at any age. The study aimed to correct the facial soft tissues of patients with undifferentiated connective tissue dysplasia through the cosmetic procedure of calcium hydroxylapatite injection. In 2018, a 36-year-old patient addressed the beauty salon with signs of undifferentiated connective tissue dysplasia, such as severe asymmetry of the face, infraorbital and nasolabial sulci, and thin and easily folding skin. Signs were observed from the age of 22, i.e., for 14 years. The therapy was performed using special features of the correction of facial soft tissue changes in patients with connective tissue dysplasia (CTD) using calcium hydroxylapatite-based products (Radiesse®, Merz North America, Inc., USA). Particular attention is given to the need for early correction to prevent premature skin aging related to this condition. After 14 days, a significant improvement of the patient's skin condition was noted after the passing of two procedures. Her condition was estimated as consistent with T1-2P0G0A1Zh1 P1M1K1 and corresponded to grade I age-related changes in the superficial soft tissues. The performed treatment showed high efficacy in case of mild connective tissue dysplasia diagnosis. The results showed that when collecting information from anamnesis, the diagnostic criteria for dysplasia should be considered. If the criteria are met, the cosmetological correction with collagen stimulators becomes possible.
ABSTRACT
BACKGROUND: This study aimed to examine the effectiveness of botulinum toxin type A (BTX-A) in the treatment of acne. METHODS: The study was conducted in 2018 on 12 patients, 10 females and two males, aged 35 years on average. The injections with BTX-A were given during 2 weeks into the face skin in a dosage of 0.125-0.250 units. RESULTS: Skin moisture indexes increased during the therapy by 4% (P ≤ 0.05), and porosity decreased by 7% (P ≤ 0.01). Maximal changes were recorded for the sulci and pigmentation of the skin, namely, its values decreased by 10 and 9%, respectively (P ≤ 0.01). BTX-A is recommended for an application not only in plastic surgeries but also for local correction of acne on the patient's skin. CONCLUSION: A positive correlation was revealed between the duration of treatment and reduction of skin oiliness (0.87), pigmentation (0.78), skin sulci (0.84), and skin porosity (0.88), and negative correlation was established with increased skin moisture (-0.64). The obtained dependencies apply for the therapy period of up to 2 weeks. Pharmacological properties of BTX-A allow recommending it as a drug used in post-acne therapy.
